Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Hoofddorp – page 48

1 940 clinical trials in Hoofddorp, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Hoofddorp at a glance
1 940
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 940 trials in Hoofddorp

Open in trial search

Study on Trastuzumab, Pertuzumab, and Tucatinib for Patients with Stage II-III HER2-Positive Breast Cancer Without Chemotherapy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Study on Adjusting Clopidogrel and Prasugrel Dosage for Patients with Chronic Coronary Syndrome Based on Body Weight

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Clopidogrel
  • Sponsor:Sint Antonius Ziekenhuis Stichting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using Daunorubicin, Mitoxantrone, and a Drug Combination

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine
  • Sponsor:Vaestra Goetalandsregionen

Ependymoma

Recruiting

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Cisplatin
  • Sponsor:Centre Leon Berard

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:The University Of Birmingham

Study on Methotrexate and Prednisone for Treating Lung Sarcoidosis in Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Methotrexate
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Study on Long-term Safety of JNJ-81201887 for Patients with Geographic Atrophy Due to Age-related Macular Degeneration

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Janssen Cilag International

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:Institut Gustave Roussy

Gastric cancer

Recruiting

Study on Pre-operative Capecitabine, Oxaliplatin, Docetaxel, and Atezolizumab for Patients with Resectable Gastric or Gastro-esophageal Junction Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Study on Reducing Treatment Frequency of Alglucosidase Alfa for Elderly Patients with Late-Onset Pompe Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Alglucosidase Alfa
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

A study of tranexamic acid to reduce blood loss during hip surgery in children with hip dysplasia and other hip conditions

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Saline
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Study on HPV Vaccine for Women with Vulvar HSIL: Evaluating the Effectiveness of Nonavalent HPV Vaccine in Preventing Recurrence of Vulvar High-Grade Lesions

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Hoofddorp

What the registry says about research in the country

01 Oncology Research

Extensive research focusing on various cancer types including breast cancer, bladder cancer, and melanoma. Studies are evaluating novel treatment combinations and maintenance therapies for improved patient outcomes.

  • Advanced/Metastatic Breast Cancer Treatments
  • Urothelial Cancer Therapies
  • Hematologic Malignancies

Multiple trials are investigating innovative approaches for both solid tumors and blood cancers, with particular emphasis on targeted therapies.

02 Hematologic Disorders

Comprehensive studies examining treatments for various blood disorders, including chronic myeloid leukemia, myelofibrosis, and lymphomas. Focus on developing targeted therapies and combination treatments.

  • B-Cell Lymphoma Treatments
  • Myelofibrosis Therapies
  • Leukemia Management

Research aims to improve treatment outcomes and quality of life for patients with blood disorders.

03 Metabolic and Surgical Studies

Research initiatives addressing obesity management and surgical conditions like appendicitis. Studies include weight management therapies and surgical technique improvements.

  • Weight Management Interventions
  • Surgical Techniques
  • Prevention Studies

Trials focus on both therapeutic and surgical interventions for better patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.